Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Christof Vulsteke, MD, PhD

home / authors / christof-vulsteke-md-phd

Christof Vulsteke, MD, PhD, is head of Integrated Cancer Center Ghent (IKG, Belgium) and Clinical Trial Unit Oncology Ghent.

Articles

Perioperative enfortumab vedotin (EV) plus pembrolizumab slashed the risk of disease progression or death by 60% in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or decline cisplatin-based chemotherapy. | Image credit: PRB Arts - stock.adobe.com

KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD

October 20th 2025

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences
AJMC®
All rights reserved.